Heart valve disease module 5: medical therapies for treatment of valvular heart disease

Released1 March 2016     Expires: 01 March 2018      Programme: Heart valve disease 1 CPD/CME credit

Sponsorship Statement: This module has been sponsored by Edwards Lifesciences with an unrestricted educational grant

Designed to give healthcare professionals a clear understanding medical therapies for the treatment of valvular heart disease. It is one of several modules in our heart valve disease programme.

1 CPD/CME credit

Module originally published July 2013. Revised module released March 2016

Learning objectives

Upon completing this module, participants should be better able to:

  • Understand the role of disease-modifying pharmacotherapy in valvular heart disease (VHD)
  • Understand the role of supportive pharmacotherapy in VHD
  • Recognise the indications for anticoagulation in VHD
  • Be aware of the patient groups at high risk of developing infective endocarditis
  • Realise the reasons for recent changes in international guidelines which restrict antibiotic prophylaxis of endocarditis
  • Compare and contrast the differing recommendations for antibiotic prophylaxis of the European Society of Cardiology and the UK National Institute for Health and Clinical Excellence.


Dr Sean Coffey, Research Fellow, Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford
Dr Bernard D Prendergast, Consultant Cardiologist, Guy’s and St Thomas’s NHS Trust, London


1 CPD/CME credit, 1 hour
BJC Learning has assigned one hour of CPD/CME credit to this module
The European Board for Accreditation in Cardiology (EBAC) has assigned one CME credit to this module. German participants should contact EBAC to receive a German VNR code for this course.
email: accreditation@ebac-cme.org
website: http://www.ebac-cme.org/

Produced in collaboration with:

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

21 thoughts on “Heart valve disease module 5: medical therapies for treatment of valvular heart disease”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.